Aligning Science Across Parkinson’s
“Aligning Science Across Parkinson’s (ASAP) is excited to be part of AMP PDRD and work towards our shared goal of accelerating discoveries for Parkinson’s disease research to ultimately propel the field closer to more therapeutic options. Fostering an open approach to research and increasing collaborations like AMP PDRD play an important role in informing the path to a cure for PD. We look forward to new insights from this research-enabling resource.”
Ekemini Riley, PhD
ASAP Managing Director
C2N Diagnostics, LLC.
“C2N Diagnostics, a specialty diagnostics company with a vision to bring Clarity Through Innovation®, believes in the work of the Accelerating Medicines Project® Parkinson’s Disease and Related Disorders (PDRD) project. Our involvement aligns with C2N’s core principles to provide exceptional clinical laboratory services and advanced diagnostic solutions in the field of brain health. Our contribution of clinically validated blood biomarkers Amyloid beta 42/40 and p-tau217 also represents the expanding scope of our focus — first, with Alzheimer’s disease and now Parkinson’s disease.”
Dr. Joel Braunstein
CEO, C2N Diagnostics
CurePSP
CurePSP proudly joins the Accelerating Medical Partnership for Parkinson’s Disease and Related Disorders. There remains a critical need for biomarkers and therapeutics for those with PSP, CBD, and MSA, and CurePSP is excited to leverage this opportunity to ensure our community is represented in this effort. We look forward to working with industry and nonprofit partners to further advancements in biomarkers and drug development for PSP, CBD, and MSA.
Kristophe Diaz, PhD
Executive Director and Chief Science Officer
Denali Therapeutics Inc.
“As a leader in the discovery and development of blood-brain barrier crossing therapies for neurodegenerative diseases, Denali is excited to be an active partner with the research community through this collaboration with the Foundation for the National Institutes of Health and Accelerating Medicines Project® Parkinson’s Disease and Related Disorders (PDRD). By working together, we aim to leverage genetic insights and biomarker-driven development to accelerate the availability of effective treatments for people living with Parkinson’s disease.”
Carole Ho, MD
Chief Medical Officer of Denali
GSK
“Parkinson’s and related diseases such as Lewy Body Dementia represent huge unmet medical need requiring novel therapeutics. However, the development of effective therapies requires a concerted effort by pooling of resources and expertise to study the natural history of disease through longitudinal characterization and development of multi-model data sets to address patient heterogeneity and to develop disease biomarkers and novel targets. All of these are integral components of the new AMP-PDRD and GSK is excited to partner with FNIH in this public-private highly collaborative endeavor to accelerate discovery and development of medicines for patients and to get ahead of the disease together.”
Sanjay Kumar
VP & GSK Senior Fellow
The Michael J. Fox Foundation
“Data sharing at this scale will accelerate the field’s progress by improving drug trials and fueling the clinical pipeline. MJFF looks forward to the results of bringing so many knowledgebases together through this public-private consortium.”
Todd Sherer, PhD
Chief Mission Officer of MJFF
Sanofi
“We are proud to be part of the Accelerating Medicines Partnership for Parkinson’s Disease and Related Disorders (AMP-PDRD). This vital collaboration with leading industry and non-profit partners supports our mission to deliver transformational innovations to those living with or at risk for synucleinopathies and their loved ones.
Building on the success of the first phase, our continued participation in AMP-PDRD demonstrates Sanofi’s commitment to open science and improving the lives of people with serious neurodegenerative diseases. ”
Dr. Pablo Sardi
Global Head of Rare and Neurologic Diseases Research Therapeutic Area, Sanofi
ACCELERATING MEDICINES PARTNERSHIP and AMP are registered service marks of the U.S. Department of Health and Human Services